Introduction
Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disorder of the gastrointestinal tract which includes Crohn's disease and Ulcerative Colitis. Both pathologies are characterized by intermittent presence of symptoms such as abdominal pain, diarrhea, blood in the stool, and systemic symptoms. 1 The incidence of IBD is usually higher in subjects between 15 and 30 years of age. 2 According to a Portuguese study by Azevedo and co-workers, the incidence of Crohn's disease was particularly higher in the age stratum between 17 and 39 years and the prevalence of IBD in Portugal in 2007 was 146 patients per 100,000 subjects, showing an increasing trend between 2003 (when it was 86 patients per 100,000 individuals) and 2007. 3 Moreover, the incidence of IBD is considered to be variable in different regions and for different groups of population, and has increased in recent years. 3, 4 Several studies report that incidence is estimated to be around 5---7 per 100,000 subjects/year for Crohn's disease in the northern hemisphere countries, such as the United States of America and northern European countries and about 0.1---4 per 100,000 subjects/year in southern countries. 3, 4 In Portugal, according to a study by Shivananda et al., between 1991 and 1993, the estimated incidence of Crohn's disease was 2.4 per 100,000 subjects and for Ulcerative colitis it was 2.9 per 100,000. 4 The treatment of IBD has focussed on the management of symptoms and, in recent years, has become more resolute on changing the course of the disease and its complications in the long-term. In fact, the probability of developing complications requiring hospitalization and surgery is high and recurrence after surgery is also common. 5---7 Therefore, in order to minimize the development of these complications and to improve outcomes for these patients, it is important to develop other strategies to manage IBD and to optimize current clinical practice.
With the main objectives of discussing ways to improve disease control in IBD, to outline key clinical data and experience leading to optimization of corticosteroid and immunosuppressive use in Crohn's disease and to debate the best practice in topics of current interest in Crohn's disease, several National Meetings were held in different countries. This article reports the main consensus statements reached in the Portuguese National Meeting.
Methodology
Between July and August 2009, 26 key unanswered practical questions on the use of conventional therapy in Crohn's disease were identified through market research. During the following months (September and October), 1400 participants from almost 30 countries evaluated those questions through a web-based ranking, giving a higher score for those considered to be the most important. Based on the ranking results, the International Steering Committee selected the top 10 questions to be debated and analysed in several National Meetings of different countries. National Meetings aimed at providing input to ascertain national perspectives to the answers.
The 10 selected questions were: After identifying the 10 questions, a specialist company was contacted to perform a literature search. Based on the literature search, a group of five bibliographic fellows from different countries, analysed the results of the search, and produced a report for each question including draft answers and supporting information with references, based on the evidence levels (Table 1) and grades of recommendation (Table 2 ) from the Oxford Centre for Evidence. 8 The report developed by the bibliographic fellows was reviewed and each of the draft answers was consolidated and approved by a group of project mentors, members of the International Steering Committee.
Methodology of the National Meeting
A National Steering Committee (NSC) was created including eight experts. Their main objective was to help elaborate the agenda, identify additional delegates with good anti-TNF therapy experience, develop/approve materials, and moderate the National Meeting with the end purpose of contributing to the development of its outputs.
During the National Meeting, the 21 participants split into five small groups (Group 1 with five members and the remaining ones with four each) to review two answered questions each. The small groups were chaired by two of the members of the NSC who presented the proposed draft answers and moderated the discussion until the group had agreed on revised wording for the answers to their selected questions. All answers were classified according to the Oxford levels of evidence (Table 1 ) and graded according to the Oxford grades of evidence ( Table 2) . 8 After reaching an agreement, all participants reconvened to present their selected answers to the entire group, followed by an overall group vote to reach a consensus for each answer. If the voting did not achieve an agreement after the initial round, participants discussed the response further and proposed a new answer, one on which an agreement could be reached. If there was no consensus after two votes, there was no further discussion. Participants voted according to a scale from 1 (strong disagreement) to 9 (strong agreement). Consensus was defined as a score of 7---9 by ≥75% of the participants. a By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant. As noted above, studies displaying worrisome heterogeneity should be tagged with a ''-'' at the end of their designated level.
Consensus
b Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.) c See note above for advice on how to understand, rate and use trials or other studies with wide confidence intervals. d Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none now die on it.
e By poor quality cohort study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-up of patients. By poor quality case-control study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
f Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into ''derivation'' and ''validation'' samples.
g An ''Absolute SpPin'' is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An ''Absolute SnNout'' is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis.
h Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference standards are haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the 'test' is included in the 'reference', or where the 'testing' affects the 'reference') implies a level 4 study.
i Validating studies test the quality of a specific diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (e.g. using a regression analysis) to find which factors are 'significant'.
j By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target outcome, or the measurement of outcomes was accomplished in <80% of study patients, or outcomes were determined in an unblinded, non-objective way, or there was no correction for confounding factors.
due to its safety profile (level of evidence: 1a; grade of recommendation: A). (3) The duration of initial treatment with conventional corticosteroids at full dose might vary depending on the response of the patient. There is no clear evidence that continuing the full dose beyond weeks 1---3 influences remission rates (level of evidence: 2b; grade of recommendation: B). 
Conclusions
The main conclusions which can be drawn after this meeting include: the importance of introducing conventional corticosteroids in moderate to severely active Crohn's disease of any localization with an initial duration of treatment varying according to patient's response; in mildly active ileocecal and/or right-sided colonic disease the use of budesonide is recommended, this being preferred to conventional corticosteroids due to its safety profile. Furthermore, neither conventional steroids nor budesonide are effective for maintenance of remission. Corticosteroids have been shown to increase the risk of serious and opportunistic infections, both independently and in combination with immunosuppressive and biologic agents. Thus, the best option to prevent steroidinduced side effects is to avoid prolonged or repetitive use and to switch appropriate patients to immunosuppressive therapy. Furthermore, the administration of immunosuppressives should be considered early in the disease course, particularly in patients at high risk of complicated disease.
For IBD the most important and, in clinical terms, most widely accepted endpoint for treatment efficacy is the remission of disease signs and symptoms. Therefore, all patients failing to respond symptomatically after adequate therapy with thiopurines or methotrexate for at least 3---months or with a biologic for at least 6---4 weeks are considered a treatment failure. With regards to immunossupressors and/or biologics, treatment failure should also include absence of endoscopic improvement.
The evidence that suggests that methotrexate is capable of mucosal healing is not as robust as the evidence supporting the effective and complete healing of the mucosa achieved with azathioprine, infliximab and adalimumab. Evidence also suggests that the early combination of immunosuppressive therapy in moderately active Crohn's disease is superior to standard therapy in establishing mucosal healing, mainly in patients who are naïve to both drugs. The use of non-invasive markers such as C-reactive protein and in particular faecal calprotectin may become a complementary means to endoscopy for the assessment of mucosal healing.
Concerning the risk of cancer, there is evidence supporting an increased risk of developing lymphoproliferative disorders and non-elanoma skin cancer in IBD patients treated with azathioprine. Steroids and immunosuppressives are associated with an increased risk of infection. The combination treatment, immunomodulators and corticosteroids or biologics, increases this risk.
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